H. pylori treatment
Phase 2/3Completed 0 watching 0 views this week๐ Rising
65
Development Stage
โ
Pre-clinicalโ
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Iron Deficiency Anemia
Conditions
Iron Deficiency Anemia, Helicobacter Pylori Infection
Trial Timeline
Nov 1, 2002 โ Sep 1, 2007
NCT ID
NCT00202488About H. pylori treatment
H. pylori treatment is a phase 2/3 stage product being developed by Eisai for Iron Deficiency Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00202488. Target conditions include Iron Deficiency Anemia, Helicobacter Pylori Infection.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00202488 | Phase 2/3 | Completed |
Competing Products
20 competing products in Iron Deficiency Anemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KER-047 | Keros Therapeutics | Phase 2 | 44 |
| Deferasirox | Novartis | Phase 3 | 77 |
| CSJ137 + Placebo | Novartis | Phase 1 | 33 |
| Deferasirox and Deferoxamine | Novartis | Phase 2 | 52 |
| Deferasirox | Novartis | Phase 2 | 52 |
| ICL670 | Novartis | Phase 2 | 52 |
| Deferasirox | Novartis | Approved | 85 |
| Deferasirox + Deferasirox | Novartis | Phase 2/3 | 65 |
| Desferasirox | Novartis | Approved | 85 |
| Deferasirox | Novartis | Phase 2 | 52 |
| Deferasirox | Novartis | Phase 3 | 77 |
| Deferasirox dispersible tablet + Defearisox film-coated tablet | Novartis | Phase 2 | 52 |
| deferasirox | Novartis | Approved | 85 |
| Deferasirox (ICL670) | Novartis | Phase 1/2 | 41 |
| ICL670 | Novartis | Approved | 85 |
| Deferasirox | Novartis | Phase 3 | 77 |
| Core Study: Deferasirox + Core Study: Deferoxamine + Extension: deferoxamine to deferasirox + Extension: deferasirox to deferoxamine + Deferasirox + Deferoxamine | Novartis | Phase 2 | 52 |
| Deferasirox | Novartis | Approved | 85 |
| Z-213 + Saccharated Ferric Oxide | Zeria Pharmaceutical | Phase 3 | 76 |
| Z-213 | Zeria Pharmaceutical | Phase 3 | 76 |